Recently Featured

EMA Intensifies Focus on Women’s Health in Medicines Development

August 8, 2026
The European Medicines Agency (EMA) is intensifying its efforts to integrate women’s health considerations into the development and regulation of medicines. This initiative comes in response to the recognition that women, who generally have a longer life expectancy than men, often face unique health challenges that have historically been underrepresented in clinical research and regulatory…

Ipsen bolsters rare disease pipeline in €700m Memo takeover

August 8, 2026
Ipsen has announced its acquisition of Memo for €700 million, marking a significant expansion of its rare disease pipeline. This acquisition is notable as it follows closely on the heels of Ipsen’s recent purchase of Kartos, completed on June 29, which further underscores the company’s aggressive strategy in the rare disease sector. The move comes…

Peptistar Begins Operation of Asahi Kasei’s FO-MD System at Manufacturing Scale

August 7, 2026
Japanese CDMO Peptistar has commenced the operation of Asahi Kasei’s forward osmosis–membrane distillation (FO–MD) system for the trial production of active pharmaceutical ingredients (APIs). This innovative system, first announced by Asahi Kasei in 2018, allows for the dehydration and concentration of liquids without the need for heat or pressure, significantly reducing the time required for…

Insilico Medicine, Takeda partner on AI-driven drug discovery

July 27, 2026
Insilico Medicine has entered into a strategic collaboration agreement with Takeda to deploy its AI-based Pharma.AI platform in the discovery and development of drug candidates. This partnership marks a significant advancement in the integration of artificial intelligence within the pharmaceutical research landscape, as both companies aim to leverage cutting-edge technology to expedite the drug discovery…

Ongoing Cases